TrialNature communications2025

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.

Binghe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.